File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oral arsenic trioxide incorporation into frontline treatment with all‐trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5‐year prospective study

TitleOral arsenic trioxide incorporation into frontline treatment with all‐trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5‐year prospective study
Authors
Singh, GHHKumana, CRYim, RLHHwang, YYGChan, SYTYip, SFLee, HKKMak, VLau, JSMChan, CCKho, BWong, RSMLi, WLin, SYLau, CKIp, HWLeung, RYYLam, CCKKwong, YL
Keywordsinduction
leukemia-free survival
maintenance
newly diagnosed acute promyelocytic leukemia
oral arsenic trioxide
Issue Date2019
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
Citation
Cancer, 2019, v. 125 n. 17, p. 3001-3012 How to Cite?
DOI: http://dx.doi.org/10.1002/cncr.32180
Persistent Identifierhttp://hdl.handle.net/10722/270090
ISSN
0008-543X
2021 Impact Factor: 6.921
2020 SCImago Journal Rankings: 3.052
ISI Accession Number ID
WOS:000480603300015

 

DC FieldValueLanguage
dc.contributor.authorSingh, GHH-
dc.contributor.authorKumana, CR-
dc.contributor.authorYim, RLH-
dc.contributor.authorHwang, YYG-
dc.contributor.authorChan, SYT-
dc.contributor.authorYip, SF-
dc.contributor.authorLee, HKK-
dc.contributor.authorMak, V-
dc.contributor.authorLau, JSM-
dc.contributor.authorChan, CC-
dc.contributor.authorKho, B-
dc.contributor.authorWong, RSM-
dc.contributor.authorLi, W-
dc.contributor.authorLin, SY-
dc.contributor.authorLau, CK-
dc.contributor.authorIp, HW-
dc.contributor.authorLeung, RYY-
dc.contributor.authorLam, CCK-
dc.contributor.authorKwong, YL-
dc.date.accessioned2019-05-20T05:09:22Z-
dc.date.available2019-05-20T05:09:22Z-
dc.date.issued2019-
dc.identifier.citationCancer, 2019, v. 125 n. 17, p. 3001-3012-
dc.identifier.issn0008-543X-
dc.identifier.urihttp://hdl.handle.net/10722/270090-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741-
dc.relation.ispartofCancer-
dc.rightsThis is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectinduction-
dc.subjectleukemia-free survival-
dc.subjectmaintenance-
dc.subjectnewly diagnosed acute promyelocytic leukemia-
dc.subjectoral arsenic trioxide-
dc.titleOral arsenic trioxide incorporation into frontline treatment with all‐trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5‐year prospective study-
dc.typeArticle-
dc.identifier.emailSingh, GHH: gillhsh@hku.hk-
dc.identifier.emailYim, RLH: ritayim@hku.hk-
dc.identifier.emailHwang, YYG: yyhwang@hku.hk-
dc.identifier.emailChan, SYT: drtchan@hku.hk-
dc.identifier.emailIp, HW: iphowan@hku.hk-
dc.identifier.emailLeung, RYY: leungyyr@hku.hk-
dc.identifier.emailLam, CCK: ccklam@hku.hk-
dc.identifier.emailKwong, YL: ylkwong@hkucc.hku.hk-
dc.identifier.authoritySingh, GHH=rp01914-
dc.identifier.authorityKwong, YL=rp00358-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/cncr.32180-
dc.identifier.scopuseid_2-s2.0-85065981030-
dc.identifier.hkuros297864-
dc.identifier.volume125-
dc.identifier.issue17-
dc.identifier.spage3001-
dc.identifier.epage3012-
dc.identifier.isiWOS:000480603300015-
dc.publisher.placeUnited States-
dc.identifier.issnl0008-543X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats